Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Classical hematology 1

Conditions

Neoplasms 1Myelodysplastic Syndromes 1Leukemia 1Anemia, Refractory 1

Interventions

fludarabine phosphate 58Cyclophosphamide 54Epoetin Alfa 43Cyclosporine 43Busulfan 43Peripheral Blood Stem Cell Transplantation 39Mycophenolic Acid 34Darbepoetin alfa 33Antilymphocyte Serum 31Whole-Body Irradiation 30Cytarabine 30Filgrastim 29Methotrexate 26Tacrolimus 25Radiotherapy 25Melphalan 24fludarabine 21Methylprednisolone 17Cord Blood Stem Cell Transplantation 17Etoposide 14Granulocyte Colony-Stimulating Factor 13Daunorubicin 13Rivaroxaban 12apixaban 11Thiotepa 11sargramostim 10epoetin beta 10Dalteparin 10eltrombopag 9Alemtuzumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Abatacept × Classical hematology × Clear all
NCT01012492 2019-11-21

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT

Boston Children's Hospital

Phase 2 Completed
11 enrolled 10 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Leukemia, Myelodysplastic Syndromes, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡